Ghusson Noha, Vasquez Gustavo
Sidney Kimmel Medical College at Thomas Jefferson University, Division of Infectious Diseases, 1015 Chestnut Street, Suite 1020, Philadelphia, PA 19107, USA.
Case Rep Infect Dis. 2018 Nov 12;2018:6846873. doi: 10.1155/2018/6846873. eCollection 2018.
To examine the burden of norovirus- and sapovirus-related diarrhea in renal transplant patients and to propose the use of nitazoxanide as a therapeutic option for treatment.
We reviewed three renal transplant patients with viral diarrhea requiring hospitalization due to acute renal failure and signs of graft rejection. All three patients were treated with nitazoxanide. We examined their clinical courses after therapy and compared time to resolution of symptoms and viral shedding.
In all three renal transplant patients, improvement of diarrheal illness was witnessed within one week of nitazoxanide initiation.
Infectious diarrhea remains an underestimated yet significant cause of morbidity in solid organ transplant patients. Norovirus and sapovirus are often responsible for this presentation. Nitazoxanide was used as a treatment modality with success in reduction of symptoms, decreased duration of illness, and cessation of viral shedding.
研究肾移植患者中诺如病毒和札如病毒相关腹泻的负担，并提出使用硝唑尼特作为治疗选择。
我们回顾了3例因急性肾衰竭和移植排斥迹象而需要住院治疗的病毒性腹泻肾移植患者。所有3例患者均接受了硝唑尼特治疗。我们检查了治疗后的临床病程，并比较了症状缓解时间和病毒排出时间。
在所有3例肾移植患者中，硝唑尼特开始使用后一周内腹泻病情均有改善。
感染性腹泻在实体器官移植患者中仍是一个被低估但重要的发病原因。诺如病毒和札如病毒常导致这种情况。硝唑尼特作为一种治疗方式成功地减轻了症状，缩短了病程，并停止了病毒排出。
